On November 18, 2026, the U.S. FDA approved Sanofi’s Infilbray (venglustat), the first medicine specifically approved to treat neurological manifestations of Type 3 Gaucher disease.
Approval covers adults and children weighing at least 15 kg (about 33 lb). Infilbray is an oral, once-daily drug designed to cross the blood-brain barrier.
The decision was supported by the Phase 3 LEAP2MONO study of 43 patients. At Week 52, the trial showed statistically significant improvement across neurological measures compared with imiglucerase, including measures of cognition and coordination/balance.
The approval addresses a major treatment gap:
existing enzyme replacement therapy can treat systemic symptoms, but had not been approved to treat the neurological symptoms of Type 3 Gaucher disease.
Sources:
FDA Approves First Drug to Treat Neurological Symptoms of Type 3 ...
Press Release: Sanofi's Infilbray approved in the US as the first ...
FDA approves first-ever med for neurological problems in Gaucher
Sanofi gains FDA clearance for Gaucher disease pill
Type 3 Gaucher Disease: FDA Approves First Drug for Neurological Symptoms After 43-Patient Trial
Sanofi Wins First U.S. Approval For Neurological Symptoms Of Type 3 Gaucher Disease
FDA approves Sanofi's Infilbray for GD3 in the U.S.
Sanofi's Infilbray wins first approval for neurological symptoms of Gaucher
Sanofi Receives FDA Approval for Type 3 Gaucher Disease Drug
Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
Sanofi's pill becomes first US-approved drug for rare neurological disorder
Sanofi Gets U.S. Approval for Rare Disease Drug
Infilbray (venglustat): FDA approval, pivotal trial and safety | 2 Minute Medicine